The venous thromboembolism (VTE) treatment market is projected to be valued at USD 1,760.42 million in 2024. With a steady growth trajectory, the market is expected to increase to USD 2,580.90 million by 2034, representing a CAGR of 3.9% during the forecast period.
The growth of the VTE treatment market is primarily driven by the rising incidence of venous thromboembolism cases and the increasing awareness of its associated risks. As healthcare providers prioritize effective treatment strategies to manage this condition, the demand for innovative therapeutic solutions is expected to surge.
This anticipated growth underscores the increasing focus on managing and treating venous thromboembolism, a condition that encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE). The market expansion is driven by advancements in treatment options, increasing awareness of VTE risks, and the rising prevalence of risk factors associated with thromboembolism.
Venous thromboembolism treatment involves segmented pneumatic compression pumps without gradient, segmented pneumatic compression pumps with calibrated gradient, lower pneumatic compression sleeves, non-segmented pneumatic compression pumps permanent inferior vena cava filters, retrievable inferior vena cava filters, embolectomy balloon catheters, percutaneous thrombectomy devices, catheter-directed thrombolysis (CDT) devices and upper pneumatic compression sleeves. Based on the disease indication, deep vein thrombosis is expected to hold a prominent share in the overall Global Venous Thromboembolism Treatment Industry.
Poor Reimbursement Scenario Against High Treatment Costs to Restrict Adoption
Several factors are impacting the overall growth of the Global Venous Thromboembolism Treatment Industry. The first and most important factor driving the venous thromboembolism treatment market is the increasing prevalence of venous thromboembolism disease. Other factors, such as the increasing retrieval rate of vena cava filters, increasing healthcare awareness, presence of favorable reimbursement policies, and the increasing geriatric population, are also responsible for the growth of the Global Venous Thromboembolism Treatment Industry.
Apart from the driving factors of the venous thromboembolism treatment market, few factors are likely to hinder the overall growth of the Global Venous Thromboembolism Treatment Industry. The high cost associated with venous thromboembolism treatment therapy, poor reimbursement for some of the treatment devices, and poor insurance support are among the major factors that are expected to hamper the growth of the Global Venous Thromboembolism Treatment Industry.
Drug-based Treatment Witnessing Traction across Europe
Although increasing preference for drug-based venous thromboembolism treatment is highly likely to hinder the growth of the market, new-generation drugs, including non-vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban, are estimated to boost the adoption rate of venous thromboembolism treatment due to increased efficacy. However, there are regional variations to this trend.
North America is expected to be a prominent region in the Global Venous Thromboembolism Treatment Industry because of the presence of a well-developed healthcare infrastructure and numerous technological advancements in the region. The increasing prevalence of venous thromboembolism is also responsible for boosting the growth of the North American market. Treatment using mechanical and interventional prophylaxis systems is expected to be increasingly adopted in the North American region during the forecast period. In addition, drug-based treatment is expected to gain popularity in the European region, which is expected to subsequently decrease the usage of mechanical and interventional treatments in the region.
On the other hand, increasing per capita healthcare expenditure is one of the macroeconomic factors that is likely to boost the market. Nowadays, certain changes in the socio-economic scenario can also lead to significant growth in the venous thromboembolism treatment market.
Tier 1 Players Account for Nearly 35% Market Revenue Share
Some of the key manufacturers of venous thromboembolism treatment are mainly focusing on innovating and launching new and advanced products. Major players in the Global Venous Thromboembolism Treatment Industry are focusing on collaborations and acquisitions. For example, venous thromboembolism treatment is majorly adopted by hospitals, catheterization laboratories, and ambulatory surgical centers. Hospitals are expected to hold a significant revenue share in the Global Venous Thromboembolism Treatment Industry.
The report tracks some of the key companies operating in the venous thromboembolism treatment market such as ArjoHuntleigh AB, AngioDynamics, Cardinal Health Inc., BTG International Ltd., Stryker Corporation, DJO Global Inc., EKOS Corp, Teleflex Inc., Boston Scientific Corp. several other companies are operating in the Global Venous Thromboembolism Treatment Industry. AngioDynamics, Boston Scientific Corp., and Cardinal Health Inc. are expected to hold a prominent share in the venous thromboembolism treatment market. These tier 1 companies hold a share of approximately 35% in the Global Venous Thromboembolism Treatment Industry.
A Old Full Report Analysis Click Here
Global Venous Thromboembolism Treatment Industry by Category by Product:
- Non-Segmented Pneumatic Compression Pumps
- Segmented Pneumatic Compression Pumps without Gradient
- Segmented Pneumatic Compression Pumps with Calibrated Gradient
- Upper Pneumatic Compression Sleeves
- Lower Pneumatic Compression Sleeves
- Permanent Inferior Vena Cava Filters
- Retrievable Inferior Vena Cava Filters
- Embolectomy Balloon Catheters
- Percutaneous Thrombectomy Devices
- Catheter-Directed Thrombolysis (CDT) Devices
By Disease Indication:
- Deep Venous Thrombosis
- Pulmonary Embolism
By End User:
- Hospitals
- Catheterisation Laboratories
- Ambulatory Surgical Centers
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
